HistoSonics, Inc. - Comprehensive Analysis Report

Summary

HistoSonics, Inc. is a pioneering medical technology company founded in 2009 by scientists and engineers from the University of Michigan, who developed the science of histotripsy. The company is dedicated to revolutionizing tissue ablation and treatment through non-invasive medical technologies. Its core mission is to advance the novel science of histotripsy and its powerful benefits, bringing meaningful and transformational change to physicians and their patients. HistoSonics envisions becoming the global leader in non-invasive medical technologies, committed to continuous improvement and excellence, and striving to make non-invasive treatments the standard of care accessible worldwide. Operating primarily in the medical devices industry, HistoSonics is recognized for its innovative approach to precisely targeting and destroying tissue without harming surrounding structures, offering reduced recovery times and minimal side effects compared to traditional surgical methods. Headquartered in Plymouth, Minnesota, with additional offices and research facilities in Ann Arbor and Minneapolis, HistoSonics was recently acquired in August 2025 for $2.25 billion by a syndicate of globally recognized private and public investors, and plans to remain private to scale faster.

1. Strategic Focus & Objectives

Core Objectives

HistoSonics' strategic focus centers on advancing the science of histotripsy and bringing its transformative benefits to global healthcare. Key objectives include:

The commercialization of its flagship product, the Edison System, in the United States and select global markets for treating liver tumors.

Concurrently, the company is dedicated to expanding histotripsy applications to other organs, including the kidney, pancreas, and prostate.

Specialization Areas

HistoSonics specializes in:

Advancing the science and application of histotripsy.

Developing and commercializing non-invasive therapeutic technologies.

Utilizing focused ultrasound technology to deliver proprietary sonic beam therapy, which mechanically destroys unwanted tissue and tumors.

Target Markets

The company’s primary market is the medical devices sector, with a specific focus on transforming tumor treatment through advanced non-invasive therapeutic technologies.

2. Financial Overview

Funding History

HistoSonics, Inc. has raised approximately $334.57 million across 14 funding rounds, establishing itself as a well-capitalized innovator in the medical devices sector. In August 2025, the company announced a significant $2.25 billion majority acquisition by a syndicate of globally recognized private and public investors, with plans to remain private for accelerated scaling.

Detailed breakdown of recent funding rounds includes:

July 31, 2024: Raised $102 million in a Series D round.

Key Investors: Alpha Wave Global, Johnson & Johnson (JJDC), Varian, SWIB, K5 Global, Jeff Bezos (Bezos Expeditions), and Wellington Management.

Fund Utilization: This funding was earmarked for accelerating advancements in its histotripsy platforms, supporting US and global commercial growth, and initiating the pivotal BOOMBOX Master Study for liver tumor treatment using the Edison System.

December 13, 2022: Secured $85 million in an earlier Series D round.

Fund Utilization: This capital was directed towards continuing product development and expanding the market reach of its histotripsy therapy platforms, aiming to deepen clinical and commercial momentum.

November 25, 2020: Obtained $15 million in conventional debt financing.

Fund Utilization: This was used to support operational scalability and overall company growth.

June 12, 2020: Raised $40.8 million in a Series C round.

Fund Utilization: Employed for next-generation product development and clinical trials.

April 9, 2019: Secured $54 million in a Series C round.

Fund Utilization: Utilized for clinical development and early commercialization efforts.

May 16, 2014: Completed its initial Series A round, raising $8.1 million.

Fund Utilization: Dedicated to early product development and commercialization.

3. Product Pipeline

Key Products/Services

Edison® System (for Liver Tumors)

Description: An autonomous robotic platform designed to deliver HistoSonics’ proprietary sonic beam therapy.

Development Stage: Received FDA De Novo clearance in October 2023 for the non-invasive mechanical destruction of liver tumors, including unresectable liver tumors. The pivotal BOOMBOX Master Study for liver tumor treatment using the Edison System has been initiated.

Target Market/Condition: Patients with liver tumors.

Expected Timeline: Commercialization is ongoing in the US and select global markets.

Key Features and Benefits: Utilizes a non-invasive, non-thermal mechanical approach to precisely destroy targeted tissue. Offers advanced imaging and proprietary software for real-time treatment effect monitoring. Provides patient-specific treatments without the need for incisions, needles, or radiation. The system has been used to treat over 1,000 patients for liver tumors at nearly 50 active centers across the US, one in the United Arab Emirates, and one in Hong Kong.

Histotripsy for Kidney Renal Masses

Description: Application of the histotripsy technology to treat renal masses.

Development Stage: The #HOPE4KIDNEY pivotal Investigational Device Exemption (IDE) trial for renal masses is nearing completion. A current clinical trial for kidney histotripsy, known as the CAIN Trial, is ongoing in the UK.